{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T22:41:12Z","timestamp":1759704072960,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Angiopoietin 2 (Ang-2) is a growth factor in angiogenesis, causing pericyte migration and vascular regression, leading to increased vascular permeability. Inflammatory mediators, hypoxia, hyperglycaemia and cancer stimulate its secretion. Particularly in sepsis, high Ang-2 levels appear to be a prognostic marker for morbidity and mortality in the critically ill. As an important trigger for endothelial damage one therapeutic option in these patients might be the removal of Ang-2. The Cyto-SOLVE trial included patients with septic shock or rhabdomyolsis treated with the adsorber Cytosorb (CS) (included in continuous kidney replacement therapy) for the removal of cytokines and myoglobin. Ang-2 was measured in the patient\u00b4s blood and pre- and post-CS at defined time points (ten minutes, one, three, six, and twelve hours after initiation). Ang-2 extracorporeal clearances (ml\/min) were calculated with: <jats:inline-formula>\n              <jats:tex-math>$$\\:\\left(bloodflow*\\left(1-hematocrit\\right)\\right)*\\left(\\frac{concentration\\:\\left(pre-post\\right)}{concentration\\:\\left(pre\\right)}\\right).$$<\/jats:tex-math>\n            <\/jats:inline-formula>\n            <jats:italic>U<\/jats:italic>-Test was used to compare different subgroups. 26 patients were included (17 with rhabdomyolsis and 9 with septic shock, median Ang-2 concentration prior to CS-application: 21,653 pg\/ml). We observed a low Ang-2 adsorption in the first hour of CS application, resulting in a median Ang-2 extracorporeal clearance of 8.2\u00a0ml\/min and 1.7\u00a0ml\/min after 10\u00a0min and 1\u00a0h, respectively. There was no significant change in Ang-2 plasma concentrations at any time point. No significant difference in Ang-2 levels was observed between patients with septic shock (median: 31,916 pg\/ml) and rhabdomyolysis (median 18,379 pg\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.241). The Cytosorb adsorber does not decrease Ang-2 concentrations by adsorption. Therefore, Ang-2 can be considered a reliable biomarker for endothelial dysfunction even in the presence of Cytosorb therapy in critically ill patients. Further studies should be conducted to determine whether the removal of Ang-2 could be beneficial when utilizing an appropriate device.<\/jats:p>","DOI":"10.1038\/s41598-025-21215-y","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:23:15Z","timestamp":1759310595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Angiopoietin-2 adsorption attempt with the cytokine adsorber cytosorb in critically ill patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Helen","family":"Graf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Gr\u00e4fe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Habler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Ewert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Wilfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Liebchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Hackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"2","key":"21215_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10456-009-9147-3","volume":"12","author":"M Thomas","year":"2009","unstructured":"Thomas, M. & Augustin, H. G. The role of the angiopoietins in vascular morphogenesis. Angiogenesis. 12 (2), 125\u2013137 (2009).","journal-title":"Angiogenesis"},{"issue":"20","key":"21215_CR2","doi-asserted-by":"publisher","first-page":"20126","DOI":"10.1074\/jbc.M500292200","volume":"280","author":"KT Kim","year":"2005","unstructured":"Kim, K. T. et al. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J. Biol. Chem. 280 (20), 20126\u201320131 (2005).","journal-title":"J. Biol. Chem."},{"issue":"5","key":"21215_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.str.2005.03.009","volume":"13","author":"WA Barton","year":"2005","unstructured":"Barton, W. A., Tzvetkova, D. & Nikolov, D. B. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure. 13 (5), 825\u2013832 (2005).","journal-title":"Structure"},{"key":"21215_CR4","doi-asserted-by":"crossref","unstructured":"Akwii, R. G., Sajib, M. S., Zahra, F. T. & Mikelis, C. M. Role of Angiopoietin-2 in vascular physiology and pathophysiology. Cells. ;8(5). (2019).","DOI":"10.3390\/cells8050471"},{"issue":"39","key":"21215_CR5","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1038\/sj.onc.1203800","volume":"19","author":"I Kim","year":"2000","unstructured":"Kim, I. et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3\u2019-kinase\/Akt signal transduction pathway. Oncogene. 19 (39), 4549\u20134552 (2000).","journal-title":"Oncogene"},{"issue":"8","key":"21215_CR6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/MCB.01472-08","volume":"29","author":"HT Yuan","year":"2009","unstructured":"Yuan, H. T., Khankin, E. V., Karumanchi, S. A. & Parikh, S. M. Angiopoietin 2 is a partial agonist\/antagonist of Tie2 signaling in the endothelium. Mol. Cell. Biol. 29 (8), 2011\u20132022 (2009).","journal-title":"Mol. Cell. Biol."},{"issue":"11","key":"21215_CR7","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","volume":"103","author":"U Fiedler","year":"2004","unstructured":"Fiedler, U. et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103 (11), 4150\u20134156 (2004).","journal-title":"Blood"},{"issue":"10","key":"21215_CR8","doi-asserted-by":"publisher","first-page":"Fso825","DOI":"10.2144\/fsoa-2022-0077","volume":"8","author":"LT Thanh Duyen","year":"2022","unstructured":"Thanh Duyen, L. T. et al. Prognostic significance of the angiopoietin-2 for early prediction of septic shock in severe sepsis patients. Future Sci. OA. 8 (10), Fso825 (2022).","journal-title":"Future Sci. OA"},{"key":"21215_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jcrc.2018.01.010","volume":"45","author":"XW Liu","year":"2018","unstructured":"Liu, X. W. et al. Sustained increase in angiopoietin-2, heparin-binding protein, and procalcitonin is associated with severe sepsis. J. Crit. Care. 45, 14\u201319 (2018).","journal-title":"J. Crit. Care"},{"issue":"11","key":"21215_CR10","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/CCM.0000000000001853","volume":"44","author":"J Fisher","year":"2016","unstructured":"Fisher, J. et al. Elevated plasma Angiopoietin-2 levels are associated with fluid overload, organ dysfunction, and mortality in human septic shock. Crit. Care Med. 44 (11), 2018\u20132027 (2016).","journal-title":"Crit. Care Med."},{"issue":"4","key":"21215_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/CCM.0b013e318206d285","volume":"39","author":"DR Ricciuto","year":"2011","unstructured":"Ricciuto, D. R. et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit. Care Med. 39 (4), 702\u2013710 (2011).","journal-title":"Crit. Care Med."},{"issue":"11","key":"21215_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/CCM.0000000000003899","volume":"47","author":"DJ Henning","year":"2019","unstructured":"Henning, D. J. et al. Physician judgment and circulating biomarkers predict 28-Day mortality in emergency department patients. Crit. Care Med. 47 (11), 1513\u20131521 (2019).","journal-title":"Crit. Care Med."},{"issue":"1","key":"21215_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-023-04525-3","volume":"27","author":"CM Rosenberger","year":"2023","unstructured":"Rosenberger, C. M. et al. Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis. Crit. Care. 27 (1), 234 (2023).","journal-title":"Crit. Care"},{"issue":"1","key":"21215_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13054-023-04554-y","volume":"27","author":"MR Atreya","year":"2023","unstructured":"Atreya, M. R. et al. Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: risk-stratified analysis from a prospective observational cohort of pediatric septic shock. Crit. Care. 27 (1), 260 (2023).","journal-title":"Crit. Care"},{"issue":"1","key":"21215_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13613-023-01165-2","volume":"13","author":"J Wollborn","year":"2023","unstructured":"Wollborn, J. et al. Angiopoietin-2 is associated with capillary leak and predicts complications after cardiac surgery. Ann. Intensive Care. 13 (1), 70 (2023).","journal-title":"Ann. Intensive Care"},{"issue":"1","key":"21215_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13054-021-03474-z","volume":"25","author":"WK Yu","year":"2021","unstructured":"Yu, W. K. et al. Angiopoietin-2 outperforms other endothelial biomarkers associated with severe acute kidney injury in patients with severe sepsis and respiratory failure. Crit. Care. 25 (1), 48 (2021).","journal-title":"Crit. Care"},{"issue":"1","key":"21215_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13054-016-1385-3","volume":"20","author":"C Robinson-Cohen","year":"2016","unstructured":"Robinson-Cohen, C. et al. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit. Care. 20 (1), 207 (2016).","journal-title":"Crit. Care"},{"issue":"3","key":"21215_CR18","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/cc13876","volume":"18","author":"KL Liu","year":"2014","unstructured":"Liu, K. L. et al. Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit. Care. 18 (3), R100 (2014).","journal-title":"Crit. Care"},{"key":"21215_CR19","doi-asserted-by":"crossref","unstructured":"Szymczak, A. et al. High plasma Angiopoietin-2 levels predict the need to initiate dialysis within two years in patients with chronic kidney disease. Int. J. Mol. Sci. 24(12). (2023).","DOI":"10.3390\/ijms241210036"},{"issue":"7","key":"21215_CR20","doi-asserted-by":"publisher","first-page":"e08253","DOI":"10.15252\/emmm.201708253","volume":"13","author":"KA Khan","year":"2021","unstructured":"Khan, K. A., Wu, F. T., Cruz-Munoz, W. & Kerbel, R. S. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol. Med. 13 (7), e08253 (2021).","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"21215_CR21","doi-asserted-by":"publisher","first-page":"R261","DOI":"10.1186\/cc10523","volume":"15","author":"P Kumpers","year":"2011","unstructured":"Kumpers, P. et al. The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit. Care. 15 (5), R261 (2011).","journal-title":"Crit. Care"},{"issue":"7","key":"21215_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1517\/13543784.2013.793306","volume":"22","author":"Z Eroglu","year":"2013","unstructured":"Eroglu, Z., Stein, C. A. & Pal, S. K. Targeting angiopoietin-2 signaling in cancer therapy. Expert Opin. Investig. Drugs. 22 (7), 813\u2013825 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"21215_CR23","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","volume":"17","author":"GD Panos","year":"2023","unstructured":"Panos, G. D. et al. Faricimab: transforming the future of macular diseases treatment\u2014A comprehensive review of clinical studies. Drug Des. Dev. Ther. 17, 2861\u20132873 (2023).","journal-title":"Drug Des. Dev.Ther."},{"issue":"5","key":"21215_CR24","first-page":"1038","volume":"104","author":"S Lovric","year":"2010","unstructured":"Lovric, S. et al. Removal of elevated circulating angiopoietin-2 by plasma exchange\u2014a pilot study in critically ill patients with thrombotic microangiopathy and anti-glomerular basement membrane disease. Thromb. Haemost. 104 (5), 1038\u20131043 (2010).","journal-title":"Thromb. Haemost"},{"key":"21215_CR25","unstructured":"Cytosorb\u00ae. Cytosorb\u00ae Technische Daten 2023. https:\/\/cytosorb-therapy.com\/de\/der-adsorber\/technische-daten-des-cytosorb-adsorber\/"},{"issue":"5","key":"21215_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5301\/ijao.5000591","volume":"40","author":"KS Houschyar","year":"2017","unstructured":"Houschyar, K. S. et al. Continuous hemoadsorption with a cytokine adsorber during sepsis\u2014a review of the literature. Int. J. Artif. Organs. 40 (5), 205\u2013211 (2017).","journal-title":"Int. J. Artif. Organs"},{"issue":"1","key":"21215_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13054-021-03468-x","volume":"25","author":"C Scharf","year":"2021","unstructured":"Scharf, C. et al. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit. Care. 25 (1), 41 (2021).","journal-title":"Crit. Care"},{"issue":"6","key":"21215_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000505899","volume":"49","author":"O Dilken","year":"2020","unstructured":"Dilken, O. et al. Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb\u00ae). Blood Purif. 49 (6), 743\u2013747 (2020).","journal-title":"Blood Purif."},{"issue":"1","key":"21215_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13613-024-01334-x","volume":"14","author":"H Graf","year":"2024","unstructured":"Graf, H. et al. Myoglobin adsorption and saturation kinetics of the cytokine adsorber Cytosorb\u00ae in patients with severe rhabdomyolysis: a prospective trial. Ann. Intensive Care. 14 (1), 96 (2024).","journal-title":"Ann. Intensive Care"},{"issue":"7","key":"21215_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1164\/rccm.201208-1460OC","volume":"187","author":"A Agrawal","year":"2013","unstructured":"Agrawal, A. et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am. J. Respir. Crit. Care Med. 187 (7), 736\u2013742 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"21215_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0310057X0603400308","volume":"34","author":"R Sanghavi","year":"2006","unstructured":"Sanghavi, R., Aneman, A., Parr, M., Dunlop, L. & Champion, D. Systemic capillary leak syndrome associated with compartment syndrome and rhabdomyolysis. Anaesth. Intensive Care. 34 (3), 388\u2013391 (2006).","journal-title":"Anaesth. Intensive Care"},{"issue":"1","key":"21215_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13613-023-01198-7","volume":"13","author":"A Greimel","year":"2023","unstructured":"Greimel, A. et al. Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study. Ann. Intensive Care. 13 (1), 110 (2023).","journal-title":"Ann. Intensive Care"},{"issue":"9","key":"21215_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s40121-024-01028-8","volume":"13","author":"H Graf","year":"2024","unstructured":"Graf, H. et al. Extracorporeal elimination of Pro- and Anti-inflammatory modulators by the cytokine adsorber CytoSorb(\u00ae) in patients with hyperinflammation: A prospective study. Infect. Dis. Ther. 13 (9), 2089\u20132101 (2024).","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"21215_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00134-025-07840-1","volume":"51","author":"A Mekontso Dessap","year":"2025","unstructured":"Mekontso Dessap, A. et al. European society of intensive care medicine (ESICM) 2025 clinical practice guideline on fluid therapy in adult critically ill patients: part 2-the volume of resuscitation fluids. Intensive Care Med. 51 (3), 461\u2013477 (2025).","journal-title":"Intensive Care Med."},{"key":"21215_CR35","first-page":"302","volume":"61","author":"CWT Gaik","year":"2020","unstructured":"Gaik, C. W. T. Rhabdomyolyse. Ein \u00dcberblick Zu Pathophysiologie, diagnostik und therapie. An\u00e4sth Intensivmed. 61, 302\u2013319 (2020).","journal-title":"An\u00e4sth Intensivmed"},{"key":"21215_CR36","doi-asserted-by":"publisher","first-page":"155029","DOI":"10.1016\/j.cyto.2020.155029","volume":"129","author":"CH Seol","year":"2020","unstructured":"Seol, C. H. et al. The ratio of plasma angiopoietin-2 to angiopoietin-1 as a prognostic biomarker in patients with sepsis. Cytokine 129, 155029 (2020).","journal-title":"Cytokine"},{"issue":"5","key":"21215_CR37","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/CCM.0b013e318241e34e","volume":"40","author":"J Hadem","year":"2012","unstructured":"Hadem, J. et al. Angiopoietin-2 in acute liver failure. Crit. Care Med. 40 (5), 1499\u20131505 (2012).","journal-title":"Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21215-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T22:02:23Z","timestamp":1759701743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21215-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21215"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21215-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the ethical review committee of the Ludwig-Maximilians-Universit\u00e4t (registration number 428\u2009-12).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"CS Speaker honoraria Cytosorbents GmbH. U.L. received consulting honoraries from CytoSorbents Europe GmbH and Medows S\u00e0rl and was part of an advisory board of Roche Diagnostics International Ltd. The other authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34294"}}